American Oriental Bioengineering(OTC) AOBI

American Oriental Bioengineering, Inc. is a biotechnology company based in Beijing, China, specializing in the development, manufacturing, and commercialization of a diverse range of pharmaceutical and healthcare products. The company offers both prescription medications and over-the-counter solutions, targeting various health conditions.

Products and Services

• Prescription medications, including Shuanghuanglian Lyophilized Injection Powder
• Over-the-counter products like Cease Enuresis Patch and Jinji Capsule
• Nutraceuticals, including soybean peptide-based beverages and supplements

Growth Outlook

• Expanding product portfolio to meet increasing healthcare demands
• Strategic distribution channels across hospitals and pharmacies in China
• Focus on research and development to innovate new healthcare solutions

Financial Highlights

• Recent quarterly revenue of $17.94 million, showing potential for recovery
• Trailing twelve months gross profit margin at 30.57%, indicating operational efficiency
• Current ratio of 0.90, suggesting adequate short-term financial health

American Oriental Bioengineering, Inc. operates in a competitive biotechnology sector, focusing on both prescription and over-the-counter products. The company has a diverse product range that addresses various health issues, from respiratory infections to menstrual discomfort. The growth outlook appears promising, with a commitment to expanding its product offerings and enhancing distribution networks across China. Recent financial data indicates a revenue of $17.94 million for the latest quarter, reflecting a potential recovery trajectory. The gross profit margin of 30.57% suggests that the company is managing its costs effectively, while a current ratio of 0.90 indicates that it is positioned to meet its short-term obligations. Overall, American Oriental Bioengineering, Inc. presents an intriguing opportunity for investors interested in the biotechnology sector.